These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31614426)

  • 1. Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers.
    Pethő L; Murányi J; Pénzes K; Gurbi B; Brauswetter D; Halmos G; Csík G; Mező G
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues.
    Rahimipour S; Ben-Aroya N; Ziv K; Chen A; Fridkin M; Koch Y
    J Med Chem; 2003 Sep; 46(19):3965-74. PubMed ID: 12954050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
    Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
    J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
    Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
    Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.
    Szabó I; Bősze S; Orbán E; Sipos É; Halmos G; Kovács M; Mező G
    J Pept Sci; 2015 May; 21(5):426-35. PubMed ID: 25908176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor.
    Lee G; Ge B
    Cancer Immunol Immunother; 2010 Jul; 59(7):1011-9. PubMed ID: 20182875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells.
    Murányi J; Gyulavári P; Varga A; Bökönyi G; Tanai H; Vántus T; Pap D; Ludányi K; Mező G; Kéri G
    J Pept Sci; 2016 Aug; 22(8):552-60. PubMed ID: 27443981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of Neurotrophin Receptors CD271 and TrkC for Prognosis, Migration, and Proliferation in Head and Neck Squamous Cell Carcinoma.
    Foerster Y; Stöver T; Wagenblast J; Diensthuber M; Balster S; Gabrielpillai J; Petzold H; Geissler C
    Cells; 2019 Sep; 8(10):. PubMed ID: 31569361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.
    Murányi J; Varga A; Gyulavári P; Pénzes K; Németh CE; Csala M; Pethő L; Csámpai A; Halmos G; Peták I; Vályi-Nagy I
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
    Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
    Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
    Hanemaaijer SH; van Gijn SE; Oosting SF; Plaat BEC; Moek KL; Schuuring EM; van der Laan BFAM; Roodenburg JLN; van Vugt MATM; van der Vegt B; Fehrmann RSN
    Oral Oncol; 2018 May; 80():33-39. PubMed ID: 29706186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel conjugation with the analog of the gonadotropin-releasing hormone as a targeting moiety.
    Pribylova M; Dvorakova M; Hanusova V; Nemethova I; Skalova L; Vanek T
    Int J Pharm; 2011 Aug; 415(1-2):175-80. PubMed ID: 21669266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma.
    Ma H; Jin S; Yang W; Zhou G; Zhao M; Fang S; Zhang Z; Hu J
    Br J Cancer; 2018 Feb; 118(4):509-521. PubMed ID: 29348488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.
    Ranđelović I; Schuster S; Kapuvári B; Fossati G; Steinkühler C; Mező G; Tóvári J
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells.
    Lajkó E; Hegedüs R; Mező G; Kőhidai L
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma.
    Lee JH; Rangappa S; Mohan CD; ; Sethi G; Lin ZX; Rangappa KS; Ahn KS
    Biomolecules; 2019 Sep; 9(10):. PubMed ID: 31575007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients?
    Montagnani Marelli M; Moretti RM; Januszkiewicz-Caulier J; Motta M; Limonta P
    Curr Cancer Drug Targets; 2006 May; 6(3):257-69. PubMed ID: 16712461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.
    Chi LH; Chang WM; Chang YC; Chan YC; Tai CC; Leung KW; Chen CL; Wu AT; Lai TC; Li YJ; Hsiao M
    Sci Rep; 2017 Aug; 7(1):9031. PubMed ID: 28831179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative assessment of the effects of integrin inhibitor cilengitide on primary culture of head and neck squamous cell carcinoma (HNSCC) and HNSCC cell lines.
    Zhang L; Gülses A; Purcz N; Weimer J; Wiltfang J; Açil Y
    Clin Transl Oncol; 2019 Aug; 21(8):1052-1060. PubMed ID: 30632010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.